Yellow Fever (YF) and Lassa Fever (LF) are two viral hemorrhagic fevers (VHFs) endemic for West and Central Africa. Among causative agents of VHFs, Lassa (LAS) and YF viruses affect the largest number of people in Africa. In endemic areas the """"""""at risk"""""""" LAS virus seronegative population may be as high as 59 million, with an annual incidence of illness of 3 million, fatalities up to 67 thousand, and up to 3 million re- infections. The sizeable disease burden and the possibility that LAS virus can be used as an agent of biological warfare make a strong case for vaccine development. There is no vaccine for LF. In contrast, attenuated YF17D, the most successful vaccine developed to date, is widely used to control YF. However, ecological and social changes, ineffective public health policy and insufficient vaccine coverage resulted in a resurgence of YF during last 15 years. Recently the YF17D vaccine has been successfully used as a vector for live vaccines against flaviviruses and as a vaccine vector for flavivirus-unrelated B and T cell epitopes. We use a full-length infectious cDNA clone of the YF17D as a vector of LAS virus genes, GPC and NP, encoding major antigens, glycoproteins and nucleoprotein, respectively. We will test the hypothesis that YF17D/LAS recombinants will effectively express LAS virus major antigens and induce protective immune responses in experimental animals. Strain 13 guinea pigs and rhesus macaques are the best experimental models for LF to comply with the FDA """"""""Two Animal Rule"""""""" for development of biodefense vaccines. Our goal is to assess the immunogenicity and efficacy of YF17D/LAS recombinants in a rodent model before pre-clinical trials in non-human primates.
Our specific aims are: 1. Generation and validation of recombinant YF17D/LAS viruses; test the hypothesis that the YF/LAS recombinants will be replication-competent and express LAS GP and NP proteins. 2. Test the hypothesis that the vaccine will induce antigen-specific responses against major LAS virus proteins. 3. Efficacy, determine whether YF17D/LAS recombinants will effectively protect strain 13 guinea pigs against LAS virus challenge. Our long-term goal is to develop a live YF17D/LAS bivalent vaccine to control YF and LF in Africa. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI068961-03
Application #
7409716
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Repik, Patricia M
Project Start
2007-05-01
Project End
2010-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
3
Fiscal Year
2008
Total Cost
$535,411
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Lukashevich, Igor S; Pushko, Peter (2016) Vaccine platforms to control Lassa fever. Expert Rev Vaccines 15:1135-50
Zapata, Juan C; Cox, Dermot; Salvato, Maria S (2014) The role of platelets in the pathogenesis of viral hemorrhagic fevers. PLoS Negl Trop Dis 8:e2858
Lukashevich, Igor S (2013) The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines 12:71-86
Zapata, Juan C; Poonia, Bhawna; Bryant, Joseph et al. (2013) An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J 10:52
Lukashevich, Igor S (2012) Advanced vaccine candidates for Lassa fever. Viruses 4:2514-57
Carrion Jr, Ricardo; Bredenbeek, Peter; Jiang, Xiaohong et al. (2012) Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. J Vaccines Vaccin 3:
Hayes, Melissa W; Carrion Jr, Ricardo; Nunneley, Jerritt et al. (2012) Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro. J Virol 86:7216-26
Jiang, Xiaohong; Dalebout, Tim J; Bredenbeek, Peter J et al. (2011) Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29:1248-57